학술논문

Novel biomarkers in the differential diagnosis of preeclampsia and lupus flare in pregnancy.
Document Type
Article
Source
Romanian Journal of Rheumatology / Revista Romana de Reumatologie. 2022, Vol. 31 Issue 2, p51-56. 6p.
Subject
*PREECLAMPSIA
*LUPUS nephritis
*PREGNANCY complications
*PREGNANCY
*SYSTEMIC lupus erythematosus
*DIFFERENTIAL diagnosis
Language
ISSN
1843-0791
Abstract
Preeclampsia and systemic lupus erythematosus are medical conditions with established elevated risks of pregnancy complications and fetal compromise. Active lupus during pregnancy can trigger the appearance of preeclampsia. Research has demonstrated an increase in lupus disease flares during pregnancy, secondary to hormonal shifts required in order to maintain pregnancy. Hemolytic anemia, leucopenia, thrombocytopenia, sudden onset of hypertension after 20 weeks of gestation and decreasing complement components such as C3, C4 and CH50 are hallmarks of lupus flares during pregnancy. Timely and accurate prediction of preeclampsia is now feasible through estimation of novel placental and endothelial biomarkers, chiefly sFlt-1 and PIGF. A sFlt-1 to PIGF ratio under 38, in patients under 34 weeks of gestation suspected of disease, boasts the highest negative predictive value for preeclampsia and can successfully rule out preeclampsia development in the following 4 weeks in patients with normal values. Moreover, the sFlt-1 to PIGF ratio has proven its utility in the differential diagnosis of preeclampsia and active lupus nephritis, with normal ratio values noted in cases of lupus flares during pregnancy. Further research is required in order to identify other novel potential biomarkers. [ABSTRACT FROM AUTHOR]